Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.56 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.54 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.50 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.50 |
| ▸ | KDM4A | O75164 | 2/20 | 0.49 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40675 | 0.82 | KDM4A (0.66) | SIGMAR1TMEM97KMT2AKDM4AKDM4C | |
| SCHEMBL13746233 | 0.81 | SMN1; SMN2 (0.53) | SIGMAR1TMEM97KMT2APYCR1PTGES | |
| SCHEMBL8987604 | 0.79 | KMT2A (0.64) | SIGMAR1TMEM97KMT2AMEN1HTT | |
| SCHEMBL535512 | 0.78 | MEP1A (0.54) | SIGMAR1TMEM97KMT2AMEN1FFAR1 | |
| SCHEMBL2634610 | 0.78 | RIPK1 (0.64) | SIGMAR1TMEM97KMT2AMEN1HTT | |
| SCHEMBL6519103 | 0.77 | KMT2A (0.50) | SIGMAR1TMEM97KMT2AMEN1HTT | |
| SCHEMBL2773041 | 0.75 | KDM4A (0.43) | SIGMAR1TMEM97KMT2AMEN1KDM4A | |
| SCHEMBL20461193 | 0.75 | KMT2A (0.48) | SIGMAR1TMEM97KMT2AMEN1HTT | |
| SCHEMBL2773039 | 0.75 | KDM4A (0.43) | SIGMAR1TMEM97KMT2AMEN1KDM4A | |
| SCHEMBL16399455 | 0.75 | PYCR1 (0.65) | SIGMAR1TMEM97PYCR1PTGESRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-8147818-B2 | inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV); useful in establishing or determining the binding site of other antiviral compounds, for example, by competitive inhibition; used to treat or prevent viral contamination of materials | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202478-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | SIGMAR1 1110/4885TMEM97 994/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.